NEW YORK, Oct. 12 - Protedyne, which develops automated technology for genomic-based drug discovery, has closed $12 million in a Series B round of private financing, the company said on Friday.

The Sprout Group, a venture capital affiliate of Credit Suisse First Boston, led the institutional placement, according to a statement. Meridian Venture Partners, Long River Ventures, and Boston Community Venture Funds participated in the round, Protedyne said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.